10 Best Healthcare Equipment Stocks to Buy According to Hedge Funds
The Healthcare Equipment segment is one of the areas across the broader healthcare landscape that carries immense innovation prospects and also offers a defensive play.
Abbott Laboratories (ABT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 11,440,255 | $1,433,349,662 | -5% | 0.49% |
| 2. | Diamond Hill Capital Ric Dillon | 5,169,513 | $647,688,284 | -8% | 3.32% |
| 3. | 2,458,000 | $307,962,820 | +32% | 0.05% | |
| 4. | Citadel Investment Group Ken Griffin | 2,080,034 | $260,607,460 | +256% | 0.04% |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,741,820 | $218,232,628 | +53% | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $108.33 | 5,033 | $545,238.98 | 6,738,817 | 2026-02-04 | Filing | |
| $109.14 | 4,967 | $542,092.42 | 6,733,784 | 2026-02-04 | Filing | |
| $107.13 | 18,800 | $2,013,966.92 | 216,203 | 2026-01-23 | Filing | |
| $122.50 | 2,040 | $249,900.00 | 7,296 | 2021-02-23 | Filing | |
| $73.40 | 2,000 | $146,798.20 | 52,562 | 2019-04-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $128.02 | 1,586 | $203,042.57 | 30,384 | 2025-11-25 | Filing | |
| $134.55 | 5,550 | $746,758.05 | 51,003 | 2025-08-08 | Filing | |
| $129.66 | 2,600 | $337,116.00 | 34,058 | 2025-04-30 | Filing | |
| $136.65 | 200 | $27,329.00 | 71,928 | 2025-03-07 | Filing | |
| $133.82 | 91,167 | $12,199,967.94 | 71,928 | 2025-03-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 175,556,716 | $21,995,500,947 | 0.32% | |
| 2. | 146,908,768 | $18,406,199,550 | 0.31% | |
| 3. | 79,853,782 | $10,004,880,347 | 0.34% | |
| 4. | 63,229,445 | $7,922,519,283 | 1.24% | |
| 5. | 39,169,239 | $4,907,523,455 | 0.91% |
News See All
Abbott Laboratories (ABT) Announces Positive Results for Amulet 360 Left Atrial Appendage (LAA) Occlude
Abbott Laboratories (NYSE:ABT) is one of the Best Dip Stocks to Buy According to Hedge Funds.
11 Best Dip Stocks to Buy According to Hedge Funds
On February 17, Mohamed El-Erian, Chief Economic Advisor at Allianz, appeared on a CNBC Television interview to discuss the way forward amidst the volatility.
Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating
Abbott Laboratories (NYSE:ABT) is one of the best 52-week low blue-chip stocks to buy right now.
10 Best 52-Week Low Blue Chip Stocks to Buy Right Now
The S&P 500 has performed exceedingly well over the past two years, powering to all-time highs amid easing inflation and the artificial intelligence boom.
Abbott (ABT) Faces Profit Headwinds as Pediatric Nutrition Remains Under Pressure
A Reuters report said Abbott Laboratories (NYSE:ABT) warned that its current-quarter profit would come in below expectations after the company also fell short of Wall Street’s revenue forecasts on January...
Abbott Laboratories (ABT): A Bull Case Theory
We came across a bullish thesis on Abbott Laboratories on R. Dennis’s SubstackR. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on ABT.
Dividend Growth Stocks: 25 Aristocrats
Dividend aristocrats are companies that have raised their dividends every year for at least 25 years.
13 Best 52-Week Low Stocks to Invest In
On January 27, Sherry Paul, a senior portfolio manager at Morgan Stanley, appeared on a CNBC Television interview to discuss the state of the markets and concerns about volatility.
Decent Organic Sales Growth Expected for Abbott Laboratories (ABT) in 2026
On January 23, Larry Biegelsen from Wells Fargo maintained an Overweight rating on Abbott Laboratories (NYSE:ABT). However, the analyst lowered the target price on the stock from $146 to $122.